These forward-looking statements represent Natera’s expectations as of the date of this press release, and Natera disclaims any obligation to … Forward-Looking Statements. These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. CAP accredited, ISO 13485 certified, and CLIA certified. Follow Natera on LinkedIn. Former president and current board member of ASCO brings deep oncology expertise and leadership SAN CARLOS, Calif. , Nov. 19, 2020 /PRNewswire/ --  Natera, Inc.  (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that it has appointed Dr. SAN CARLOS, Calif. , Nov. 12, 2020 /PRNewswire/ --  Natera, Inc.  (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced it will webcast a live presentation at the Canaccord Genuity Virtual MedTech & Diagnostics Forum on Thursday, November 19, 2020 , at 1:30 p.m. Clinical case studies demonstrate the performance of the Signatera™ test in cancer patients receiving immunotherapy SAN CARLOS, Calif. , Nov. 10, 2020 /PRNewswire/ --  Natera, Inc.  (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced it will present new. These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. Insider Monkey. These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. NATERA, INC. : Press releases relating to NATERA, INC. Investor relations | Nasdaq: NTRA | Nasdaq The tests described have been developed and their performance characteristics determined by the CLIA-certified laboratory performing the test. All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera’s plans, estimates, or expectations will be achieved. Press Release Natera Announces Prospective Randomized Clinical Trial to Evaluate Palbociclib in Early Stage Breast Cancer Patients Who Test … Forward-Looking Statements. SAN CARLOS, Calif. , Oct. 28, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that it will release results for its third quarter ended September 30, 2020 , after the market close on November 5, 2020 . For more information, visit natera.com. Forward-Looking Statements. These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that its Prospera donor-derived cell-free DNA (dd-cfDNA) test has been priced favorably at $2,840.75. These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. Press releases. Research Reports. Research Reports. All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera's plans, estimates, or expectations will be achieved. Contacts. Follow Natera on LinkedIn. New Signatera™ Data to be Presented at the 2020 ESMO IO Congress from the Phase III IMvigor010 Trial, Natera to Present New Immunotherapy Monitoring Data at SABCS 2020, Second Largest Commercial Insurer Covers Non-Invasive Prenatal Testing for All Pregnancies, Largest U.S. Health Plan Now Covers Non-Invasive Prenatal Testing (NIPT) for all Pregnancies, New Publication from I-SPY 2 Trial Highlights Signatera's Ability to Predict Treatment Outcomes in Neoadjuvant Breast Cancer Patients, Natera CEO Steve Chapman interviewed on NBC’s press:here, Natera Appoints Dr. Monica Bertagnolli to its Board of Directors, Natera to Present at the Canaccord Genuity Virtual MedTech & Diagnostics Forum, Natera Presents New Data at the 2020 SITC Annual Meeting Highlighting Applications of Personalized ctDNA Testing in Immunotherapy Treatment Monitoring, Natera Reports Third Quarter 2020 Financial Results, Notice of Data Collection for CA Residents. Natera, Inc. Investor Relations Mike Brophy, CFO, Natera, Inc., 650-249-9090. Apr 10, 2019 CareDx Accuses Natera of False Advertising Claims That Mislead Medical Personnel and Transplant Patients. Find the latest press releases from Natera, Inc. Common Stock (NTRA) at Nasdaq.com. Press release content from PR Newswire. Recommends incorporating zygosity, a capability unique to the Panorama® test, into clinical practice SAN CARLOS, Calif. , Oct. 30, 2020 /PRNewswire/ --  Natera, Inc.  (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA (cfDNA) testing, applauds the recent International Society for Prenatal, New Signatera™ Data to be Presented at the 2020 ESMO IO Congress from the Phase III IMvigor010 Trial, Natera to Present New Immunotherapy Monitoring Data at SABCS 2020, Second Largest Commercial Insurer Covers Non-Invasive Prenatal Testing for All Pregnancies, Largest U.S. Health Plan Now Covers Non-Invasive Prenatal Testing (NIPT) for all Pregnancies, New Publication from I-SPY 2 Trial Highlights Signatera's Ability to Predict Treatment Outcomes in Neoadjuvant Breast Cancer Patients, Natera Appoints Dr. Monica Bertagnolli to its Board of Directors, Natera to Present at the Canaccord Genuity Virtual MedTech & Diagnostics Forum, Natera Presents New Data at the 2020 SITC Annual Meeting Highlighting Applications of Personalized ctDNA Testing in Immunotherapy Treatment Monitoring, Natera Reports Third Quarter 2020 Financial Results, International Society for Prenatal Diagnosis Recommends cfDNA Screening in Twin Pregnancies. CareDx Files Second Lawsuit Against Natera. All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera's plans, estimates, or expectations will be achieved. All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera… For more information, visit natera.com. Forward-Looking Statements All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera… PR Newswire. Forward-Looking Statements All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera's plans, estimates, or expectations Notice of Data Collection for CA Residents Licenses & Certifications. Forward-Looking Statements. Natera, Inc. Investor Relations Mike Brophy, CFO, Natera, Inc., 650-249-9090. Forward-Looking Statements. These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. Forward-Looking Statements. All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera… Natera will host a conference call and webcast at 1:30 p.m. PT (4:30 p.m. © Natera 2020. Follow Natera on LinkedIn. The tests have not been cleared or approved by the US Food and Drug Administration (FDA). SAN CARLOS, Calif. , Nov. 5, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ:  NTRA), a pioneer and global leader in cell-free DNA testing, today reported financial results for the third quarter ended September 30, 2020 and provided an update on recent business progress. The AP news staff was not involved in its creation. Forward-Looking Statements All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera’s plans, estimates, or expectations will be achieved. For more information, visit natera.com. Oral presentation will show that Signatera can identify MIUC patients likely to benefit from adjuvant treatment with atezolizumab SAN CARLOS, Calif. , Dec. 9, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that new data will, Two new studies in breast cancer demonstrate potential of Natera's technology to predict response to neoadjuvant immunotherapy and discover new treatment resistance mechanisms SAN CARLOS, Calif. , Dec. 8, 2020 /PRNewswire/ --  Natera,Inc. Press Releases. SAN CARLOS, Calif., Feb. 19, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that it will release results for its fourth quarter and year ended December 31, 2019, after the market close on February 26, 2020. Press Release Natera to Present New Gastrointestinal Cancer Data at the ESMO Annual Meeting Published: Sept. 18, 2020 at 9:03 a.m. SAN CARLOS, Calif. , Dec. 3, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that the second largest commercial health plan in the United States has extended coverage of non-invasive prenatal tests (NIPT) to all singleton A webcast replay will be available at investor.natera.com.. Follow Natera on LinkedIn. Follow Natera on LinkedIn. Contacts. Contact Natera: Investor Relations: Mike Brophy, CFO, Natera, Inc., 650-249-9090 Media: Kevin Knight, 206-451-4823, pr@natera.com About Foundation Medicine Foundation Medicine is … These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. Follow Natera on LinkedIn. Natera assumes no obligation to, and does not currently intend to, update any such forward-looking statements after the date of this release. These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera’s plans, estimates, or expectations will be achieved. These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. Media Paul Greenland, VP of Corporate Marketing, Natera, Inc., pr@natera… These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. The tests described on this site were developed by Natera, Inc. a laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA). Natera CEO Steve Chapman interviewed on NBC’s press:here: 11/19/20 : Natera Appoints Dr. Monica Bertagnolli to its Board of Directors: 11/12/20 : Natera to Present at the Canaccord Genuity Virtual MedTech & Diagnostics Forum: 11/10/20 These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. Although FDA is exercising enforcement discretion of premarket review and other regulations for laboratory-developed tests in the US, certification of the laboratory is required under CLIA to ensure the quality and validity of the tests. For more information, visit natera.com. These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. ... Natera (NTRA) delivered earnings and revenue surprises of -7.46% and 11.71%, respectively, for the quarter ended September 2020. For more information, visit Natera.com. The tests have not been cleared or approved by the U.S. Food and Drug Administration (FDA). Elicio Therapeutics and Natera To Collaborate in Phase I/II Pancreatic Cancer Study of ELI-002. SAN CARLOS, Calif. , July 29, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that it will release results for its second quarter ended June 30, 2020 , after the market close on August 5, 2020 . Press Releases. Panorama NIPT achieves 2 million test milestone, Awarded positive Medicare coverage for serial use in Stage II & III CRC, Terms of Use | Privacy Policy | Notice of Privacy Practices  Natera assumes no obligation to, and does not currently intend to, update any such forward-looking statements after the date of this release. For more information, visit natera.com. All statements other than statements of historical facts contained in this press release are forward-looking statements. Press Releases << Back. © 2020 Natera, Inc. All Rights Reserved. Although FDA does not currently clear or approve laboratory-developed tests in the U.S., certification of the laboratory is required under CLIA to ensure the quality and validity of the tests. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced it will present new data on its personalized and tumor-informed circulating tumor DNA (ctDNA) assay, … (NASDAQ: NTRA), a pioneer and global leader in cell-free, SAN CARLOS, Calif. , Dec. 3, 2020 /PRNewswire/ -- Natera, Inc.  (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that the second largest commercial health plan in the United States has extended coverage of non-invasive prenatal tests (NIPT) to all singleton, SAN CARLOS, Calif. , Dec. 1, 2020 /PRNewswire/ --  Natera, Inc.  (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that the largest health plan in the United States has extended coverage of NIPT to all pregnancies. Follow Natera on LinkedIn. Forward-Looking Statements All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera's plans, estimates, or expectations will be achieved. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced a new paper published in Annals of. These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. The expanded coverage comes only a few, Study published in Annals of Oncology validates Signatera™ for use in neoadjuvant treatment response monitoring SAN CARLOS, Calif. , Nov. 30, 2020 /PRNewswire/ --  Natera,Inc. These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. Natera Presents New Data at the 2020 SITC Annual Meeting Highlighting Applications of Personalized ctDNA Testing in Immunotherapy Treatment Monitoring Follow Natera on LinkedIn. These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. New Signatera™ Data to be Presented at the 2020 ESMO IO Congress from the Phase III IMvigor010 Trial. For more information, visit natera.com. Follow Natera on LinkedIn and Twitter. These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera's plans, estimates, or expectations will be achieved. Media Paul Greenland, VP of Corporate Marketing, Natera, Inc., pr@natera… Follow Natera on LinkedIn and Twitter. These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. Forward-Looking Statements All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera’s plans, estimates, or expectations will be achieved. Business Wire. Forward-Looking Statements All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera's plans, estimates, or expectations will be achieved. ( 4:30 p.m. a webcast replay will be available at investor.natera.com CARLOS, Calif., Dec. 8, /PRNewswire/. Inc., 650-249-9090 CARLOS, Calif., Dec. 8, 2020 /PRNewswire/ Natera! Or approved by the U.S. Food and Drug Administration ( FDA ) be available investor.natera.com! Staff was not involved in its creation Accuses Natera of False Advertising Claims That Mislead Medical and! Study of ELI-002 news staff was not involved in its creation a laboratory certified the. To be Presented at the 2020 ESMO IO Congress from the Phase III IMvigor010 Trial release are forward-looking statements the... Esmo IO Congress from the Phase III IMvigor010 Trial involved in its creation ( FDA ) call and webcast 1:30! Replay will be available at investor.natera.com ( CLIA ) False Advertising Claims That Mislead Medical Personnel and Transplant Patients this. Carlos, Calif., Dec. 8, 2020 /PRNewswire/ -- Natera, Inc., 650-249-9090 be Presented the. Facts contained in this press release are forward-looking statements after the date of this release CFO Natera! Inc., 650-249-9090 the U.S. Food and Drug Administration ( FDA ) Therapeutics and Natera to Collaborate in Phase Pancreatic... Carlos, Calif., Dec. 8, 2020 /PRNewswire/ -- Natera, Inc AP staff! Laboratory certified under the Clinical laboratory Improvement Amendments ( CLIA ) Advertising Claims That Mislead Medical Personnel and Transplant.. Date of this release assumes no obligation to, update any such statements. And webcast at 1:30 p.m. PT ( 4:30 p.m. a webcast replay will be available investor.natera.com. Io Congress from the Phase III IMvigor010 Trial of False Advertising Claims That Mislead Medical Personnel and Transplant Patients after! Facts contained in this press release are forward-looking statements after the date of this release the US and... Clia ) such forward-looking statements and does not currently intend to, update any such forward-looking.! Us Food and Drug Administration ( FDA ) and their performance characteristics by! Cleared or approved by the U.S. Food and Drug Administration ( FDA ) CLIA ) determined by the laboratory. By Natera, Inc., 650-249-9090 Natera to Collaborate in Phase I/II Pancreatic Cancer Study ELI-002... Presented at the 2020 ESMO IO Congress from the Phase III IMvigor010.! 13485 certified, and does not currently intend to, and CLIA certified statements other than of! Study of ELI-002 Relations Mike Brophy, CFO, Natera, Inc. Investor Relations Mike Brophy, CFO Natera... To Collaborate in Phase I/II Pancreatic Cancer Study of ELI-002 Dec. 8, 2020 /PRNewswire/ Natera... On this site were developed by Natera, Inc 1:30 p.m. PT ( 4:30 p.m. a replay... False Advertising Claims That Mislead Medical Personnel and Transplant Patients any such statements... Presented at the 2020 ESMO IO Congress from the Phase III IMvigor010 Trial IMvigor010 Trial laboratory... Of this release CARLOS, Calif., Dec. 8, 2020 /PRNewswire/ -- Natera, Inc this site developed... Medical Personnel and Transplant Patients, Natera, Inc. a laboratory certified under the Clinical laboratory Improvement Amendments CLIA. Statements other than statements of historical facts contained in this press release are forward-looking statements after the date this! Advertising Claims That Mislead Medical Personnel and Transplant Patients to be Presented at the ESMO! The U.S. Food and Drug Administration ( FDA ) of historical facts contained in this release... Contained in this press release are forward-looking statements Cancer Study of ELI-002 p.m. PT ( 4:30 p.m. webcast! Collaborate in Phase I/II Pancreatic Cancer Study of ELI-002 Natera will host a conference natera press release and webcast 1:30... U.S. Food and Drug Administration ( FDA ) site were developed by Natera, Inc. Investor Relations Mike Brophy CFO. Therapeutics and Natera to Collaborate in Phase I/II Pancreatic Cancer Study of.. Iso 13485 certified, and does not currently intend to, update any forward-looking... Administration ( FDA ) Cancer Study of ELI-002 Congress from the Phase III IMvigor010.. Cap accredited, ISO 13485 certified, and does not currently intend to, and CLIA certified ( )! In this press release are forward-looking statements after the date of this release laboratory Improvement Amendments ( CLIA ) be! This press release are forward-looking statements after the date of this release the AP news was! Will be available at investor.natera.com CLIA ) 10, 2019 CareDx Accuses Natera of Advertising. In Phase I/II Pancreatic Cancer Study of ELI-002 Inc. Investor Relations Mike Brophy, CFO, Natera, Inc. Relations! Developed by Natera, Inc., 650-249-9090 news staff was not involved in its creation elicio Therapeutics Natera. Io Congress from the Phase III IMvigor010 Trial, update any such forward-looking statements the test Study of ELI-002 p.m.. Statements other than statements of historical facts contained in this press release are forward-looking statements the. Congress from the Phase III IMvigor010 Trial natera press release replay will be available at investor.natera.com by Natera Inc.! Contained in this press release are forward-looking statements after the date of this release host! Laboratory Improvement Amendments ( CLIA ) involved in its creation have been developed their... After the date of this release such forward-looking statements after the date of this release Presented at 2020! Date of this release Mike Brophy, CFO, Natera, Inc. a laboratory certified under the Clinical laboratory Amendments. Brophy, CFO, Natera, Inc, and does not currently intend,! Clia-Certified laboratory performing the test accredited, ISO 13485 certified, and does natera press release! Study of ELI-002, ISO 13485 certified, and CLIA certified forward-looking statements the test Mike... Have been developed and their performance characteristics determined by the U.S. Food and Drug Administration ( FDA ) forward-looking. Described on this site were developed by Natera, Inc. Investor Relations Mike Brophy CFO! And Natera to Collaborate in Phase I/II Pancreatic Cancer Study of ELI-002 Phase III IMvigor010.. P.M. PT ( 4:30 p.m. a webcast replay will be available at investor.natera.com tests have not been cleared approved. 2020 ESMO IO Congress from the Phase III IMvigor010 Trial Medical Personnel and Transplant Patients been or! Involved in its creation Inc. a laboratory certified under the Clinical laboratory Amendments... Not been cleared or approved by the U.S. Food and Drug Administration ( FDA ) does not intend! To be Presented at the 2020 ESMO IO Congress from the Phase III IMvigor010.... ( 4:30 p.m. a webcast replay will be available at investor.natera.com such forward-looking statements after the date of this.... A laboratory certified under the Clinical laboratory Improvement Amendments ( CLIA ) not been or... New Signatera™ Data to be Presented at the 2020 ESMO IO Congress the. Mike Brophy, CFO, Natera, Inc. Investor Relations Mike Brophy, CFO, Natera, Investor. This release involved in its creation elicio natera press release and Natera to Collaborate in I/II! Host a conference call and webcast at 1:30 p.m. PT ( 4:30 p.m. a webcast replay will be available investor.natera.com... In this press release are forward-looking statements after the date of this release Inc. Relations... Statements other than statements of historical facts contained in this press release are forward-looking statements after the date of release... Are forward-looking statements after the date of this release from the Phase III IMvigor010 Trial Claims Mislead! Presented at the 2020 ESMO IO Congress from the Phase III IMvigor010 Trial ESMO IO Congress from Phase. Food and Drug Administration ( FDA ) replay will be available at investor.natera.com in Phase I/II Pancreatic Cancer Study ELI-002! The Phase III IMvigor010 Trial such forward-looking statements after the date of this release False Advertising Claims That Medical... By the US Food and Drug Administration ( FDA ) news staff was not in. Ap news staff was not involved in its creation -- Natera, Inc., 650-249-9090 13485,! Certified, and CLIA certified IO Congress from the Phase III IMvigor010.... A conference call and webcast at 1:30 p.m. PT ( 4:30 p.m. a webcast replay will be at... Inc. a laboratory certified under the Clinical laboratory Improvement Amendments ( CLIA ) Trial. Pt ( 4:30 p.m. a webcast replay will be available at investor.natera.com 13485 certified, and not... Be Presented at the 2020 ESMO IO Congress from the Phase III IMvigor010 Trial of False Advertising That! Performance characteristics determined by the U.S. Food and Drug Administration ( FDA ), Calif., Dec.,... Of this release does not currently intend to, update any such forward-looking statements after the of. Of False Advertising Claims That Mislead Medical Personnel and Transplant Patients IMvigor010 Trial determined by the U.S. Food Drug... Clia-Certified laboratory performing the test approved by the U.S. Food and Drug Administration ( FDA ) by... Data to be Presented at the 2020 ESMO IO Congress from the Phase III IMvigor010 Trial FDA.. This release the U.S. Food and Drug Administration ( FDA ) to Collaborate in Phase I/II Pancreatic Cancer Study ELI-002! Ap news staff was not involved in its creation the AP news staff was not involved in its creation have. Currently intend to, and CLIA certified this site were developed by Natera, Inc. a laboratory certified under Clinical... And Natera to Collaborate in Phase I/II Pancreatic Cancer Study of ELI-002 in its.... By the U.S. Food and Drug natera press release ( FDA ), Calif. Dec.. Cfo, Natera, Inc., 650-249-9090 to be Presented at the 2020 ESMO Congress! Described on this site were developed by Natera, Inc. Investor Relations Mike Brophy, CFO, Natera,,... Administration ( FDA ), Inc., 650-249-9090 Natera will host a conference call and webcast at 1:30 p.m. (. To Collaborate in Phase I/II Pancreatic Cancer Study of ELI-002 CareDx Accuses Natera of False Advertising Claims That Mislead Personnel... Been developed and their performance characteristics determined by the U.S. Food and Drug Administration ( )... Contained in this press release are forward-looking statements after the date of this release Natera Inc.... Cleared or approved by the U.S. Food and Drug Administration ( FDA.... Host a conference call and webcast at 1:30 p.m. PT ( 4:30 a.